(Q33695730)

28 July 2017

1 reference

title

Nonpeptidic ligands for peptide and protein receptors (English)

1 reference

28 July 2017

Freidinger RM

1

1 reference

28 July 2017

1 August 1999

1 reference

Current Opinion in Chemical Biology

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

4

1 reference

28 July 2017

395-406

1 reference

Non-peptide ligands for peptide receptors

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Peptidomimetic design

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

L-tryptophan urea amides as NK1/NK2 dual antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

4-Alkylpiperidines related to SR-48968: potent antagonists of the neurokinin-2 (NK2) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

1-[2(R)-(2-amino-2-methylpropionylamino)-3-(1H-indol-3-yl)propionyl]- 3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and short-duration growth hormone secretagogue.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

A potent, orally bioavailable benzazepinone growth hormone secretagogue.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Novel orally active growth hormone secretagogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Stereoselective synthesis of a novel and bifunctional endothelin antagonist, IRL 3630

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Thieno[2,3-d]pyrimidine-3-acetic acids. A new class of nonpeptide endothelin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Studies on nonpeptide angiotensin II receptor antagonists. II. Synthesis and biological evaluation of 5H-pyrazolo[1,5-b][1,2,4]triazole derivatives with a C-linked oxygen functional group at the 6-position

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Synthesis of 9-deoxo-4''-deoxy-6,9-epoxyerythromycin derivatives: novel and acid-stable motilides

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. II.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

Potent, orally absorbed glucagon receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns].

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980060-X

7 January 2021

10.1016/S1367-5931(99)80060-X

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10419845